Clinical trial · no report yet · Phase 3
PrE1005
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
- NCT07285239 ↗
- Recruiting
- PrECOG, LLC.
- 15 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 15 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Arm A: Belantamab Mafodotin; Arm B: Daratumumab Hyaluronidase; Bortezomib; Lenalidomide; Dexamethasone
- Arms
- Arm A: Belantamab Mafodotin · Experimental
- Arm B: · Active comparator
- Enrollment
- 500 (estimated)
- Primary outcomes
- MRD Negative Status
- Progression-Free Survival (PFS)
- Sponsor
- PrECOG, LLC. with GlaxoSmithKline
- Start
- Sep 2026 (estimated)
- Primary completion
- Nov 2031 (estimated)
- Results posted
- No
- Registry record
- NCT07285239 · updated Aug 17, 2026